Abstract
Ever since it was introduced in routine clinical cardiology practice (1), the continuous ambulatory electrocardiogram (Holter ECG) has been routinely used for diagnostic assessment of patients with different types of heart disease like cardiac arrhythmias, transient ischemic episodes and silent myocardial ischemia. The incidence of cardiac arrhythmia and myocardial ischemia, as well as the assessment of heart rate variability on Holter ECG acquired continuously over 24 h or longer have been useful for predicting clinical disease outcomes (2–5). Likewise, Holter ECG is often used in clinical drug research for the monitoring of general cardiac safety of novel drugs under development, particularly during the early phase I trials. In contrast, Holter ECG has only rarely been used in drug development for the formal assessment of drug-induced effects on cardiac repolarization, and the experience of central ECG laboratories in measuring ECG intervals on Holter is limited. Pharmaceutical sponsors and patients alike would benefit if reliable QT/QTc assessment were possible by Holter ECG, whereby the continuous ambulatory digital 12-lead ECG would be used to substitute for standard resting supine 12-lead ECGs in the assessment of drug-induced QT/QTc prolongation.
Keywords
- Heart Rate Variability
- Cardiac Repolarization
- QTcF Change
- Clinical Drug Research
- Transient Ischemic Episode
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Holter NJ. New methods for heart studies. Science 1961;134:1214.
Atiga WL, Calkins H, Lawrence JH, et al. Beat-to-beat repolarization lability identifies patients at risk for sudden cardiac death. J Cardiovasc Electrophysiol 1998;9:899–908.
Atiga WL, Fananapazir L, McAreavey D, Calkins H, Berger RD. Temporal repolarization lability in hypertrophic cardiomyopathy caused by beta-myosin heavy-chain gene mutations. Circulation 2000;101:1224–1226.
Berger RD, Kasper EK, Baughman KL, et al. beat-to-beat QT interval variability; novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation 1997;96:1557–1565.
Vrtovec B, Starc V, Starc R. Beat-to-beat QT interval variability in coronary patients. J Electrocardiol 2000;33119-33125.
International Conference on Harmonization. The clinical evaluation of QT/QTc interval prolongation and proaarrhythmic potential for non-antiarrhythmic drugs. Preliminary Concept Paper, Step 1 Draft 4, June 10, 2004.
Yap YG, Camm AJ. Arrhythmogenic mechanisms of non-sedating antihistamines. Clin Exp Allergy 1999;29(Suppl. 3):174–181.
van Haarst AD, van’t Klooster GA, van Gerven JM et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998;64:542–546.
Morganroth J, Talbot GH, Dorr MB, et al. Effect of single, ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval). Clin Therapeutics 1999;21:818–828.
Darpö B. Spectrum of drugs prolonging the QT interval and the incidence of torsades de pointes. Eur Heart J 2001;3(Suppl. K):K70–K80.
Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovascular Research 2000;47:219–233.
Morganroth J. Focus on issues in measuring and interpreting changes in the QTc interval duration. Eur Heart J Supplements 2001;3(Suppl. K):K105–K111.
Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation. Implications for drug approval and labeling. Drug Safety 2001;24:323–351.
Shah RR. The significance of QT interval in drug development. Brit J Clin Pharmacol, 2002;54:188–202.
Committee for Proprietary Medicinal Products (CPMP). Points to Consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products, 17 December 1997.
Merri M, Moss AJ, Benhorin J, et al. Relation between ventricular repolarization duration and cardiac cycle length during 24-hour Holter recordings.
Jensen BT, Larroude CE, Rasmussen LP, et al. beat-to-beat QT dynamics in healthy subjects. Ann Noninvasive Electrocardiol 2004;9:3–11.
Pratt CM, Ruberg S, Morganroth J, et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 1996;131:472–480.
Lee K-T, Chu C-S, SU H-M,et al. Circadian variation of QT dispersion determined by twelve-lead Holter Electrocardiography. Cardiology 2003;100:101–102.
Morganroth J. Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms. Am J Cardiol 1993;72:10B–13B.
Extramiana F, Neyroud N, Huikuri HV, et al. QT interval and arrhythmic risk assessment after myocardial infarction. Am J Cardiol 1999;83:266–269.
Bonnemeier H, Hartmann F, Wiegand UK, et al. Course and prognostic implications of QT interval and QT interval variability after primary coronary angioplasty in acute myocardial infarction. J Am Coll Cardiol 2001;37:44–50.
Pohl R, Yeragani VK. QT variability in panic disorder patients after isoproterenol infusion. Int J Neuropsychopharmacol 2001;4:17–20.
Yeragani VK, Pohk R, Jampala VC, et al. Effect of posture and isoproterenol on beat-to-beat HR and QT variability. Neuropsychobiology 2000;41:113–123.
Extramiana F, Maison-Blanche P, Badilini F, et al. Circadian modulation of QT rate dependence in healthy volunteers: Gender and age differences. J Electrocardiol 1999;32:33–43.
Lande G, Funck-Brentano C, Ghadanfar M, et al. Steady-state vs. non-steady-state QT-RR relationships in 24-hour Holter recordings. Pacing Clin Electrophysiol 2000;23:293–302.
Lang CC, Flapan AD, Neilson JM. The impact of QT lag compensation on dynamic measurement of ventricular repolarization: Reproducibility and the impact of lead selection. Pacing Clin Electrophysiol 2001;24:366–373.
Sarma JS, Venkataraman SK, Samant DR, et al. Hysteresis in the human RR-QT relationship during exercise and recovery. Pacing Clin Electrophysiol 1987;10:485–491.
Yamada A, Hayano J, Horie K, et al. Regulation of QT interval during postural transitory changes in heart rate in normal subjects. Am J Cardiol 1993;71:996–998.
Bosner MS, Kleiger RE. Heart rate variability and risk stratification after myocardial infarction. In Malik M, Camm AJ (eds). Heart rate variability. Futura, Armonk, NY, 1995, pp. 331–340.
Atildsen H, Christiansen EH, Pedersen AK, et al. Reproducibility of QT parameters derived from 24-hour ambulatory ECG recordings in healthy subjects. Ann Noninvasive Electrocardiol 2001;6:24–31.
Copie X, Alonso C, Lavergne T, et al. Reproducibility of Qt interval measurements obtained from 24-hour digitized ambulatory three-lead electrocardiograms in patients with acute myocardial infarction and healthy volunteers. Ann Noninvasive Electrocardiol 1998;3:38–45.
Savelieva I, Yap YG, Yi G, et al. Comparative reproducibility of QT, QT peak, and T peak — T end intervals and dispersion in normal subjects, patients with myocardial infarction and patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 1998;21:2376–2381.
Baranowski R, Poplawska W, Buchner T, et al. day-to-day reproducibility of Holter beat-by-beat analysis of repolarization. Acta Cardiol 2003;58:185–189.
Sarapa N, Morganroth J, Couderc JP, et al. Electrocardiographic Identification of Drug-Induced QT Prolongation: Assessment by Different Recording and Measurement Methods. Ann Noninvasive Electrocardiol 2004;9:48–57.
Morganroth J, Silber SS. How to obtain and analyze electrocardiograms in clinical trials: Focus on issues in measuring and interpreting changes in the QTc interval duration. A N E 1999;4:425–433.
Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8:135–160.
Malik M, Bradford A. Human precision of operating a digitizing board: implications for electrocardiogram measurements. PACE 1998;21:1656–1662.
Food and Drug Administration and Health Canada. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Preliminary Concept paper, November 15, 2002 http://www.fda.gov/cder/workshop.htm#upcoming.
Kautzner J, Gang Y, Camm AJ, et al. Short-and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. PACE 1994;17:928–937.
Kautzner J, Gang Y, Kishore AGR, et al. Interobserver reproducibility of QT interval measurement and QT dispersion in patient after acute myocardial infarction. Ann Noninvas Electrocardiol 1996;1:363–374.
Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation. Implications for drug approval and labeling. Drug Safety 2001;24:323–351.
Malik M, Färbom P, Batchvarov V, et al. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 2002;87:220–228.
Darpö B, Almgren O, Bergstrand R, et al. Assessment of frequency-dependency of the class III effects of almokalant. A study using programmed stimulation and recordings of monophasic action potentials and ventricular paced QT-intervals. Cardiovasc Drug Therapy 1996;10:539–554.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Sarapa, N. (2005). Digital 12-Lead Holter vs Standard Resting Supine Electrocardiogram for the Assessment of Drug-Induced QTc Prolongation. In: Morganroth, J., Gussak, I. (eds) Cardiac Safety of Noncardiac Drugs. Humana Press. https://doi.org/10.1007/978-1-59259-884-7_8
Download citation
DOI: https://doi.org/10.1007/978-1-59259-884-7_8
Publisher Name: Humana Press
Print ISBN: 978-1-58829-515-6
Online ISBN: 978-1-59259-884-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)